Roche’s cobas SARS-CoV-2 test receives FDA emergency use authorization
First commercial test will enable expedited coronavirus testing to meet urgent medical needs
13 Mar 2020
Roche has announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the cobas® SARS-CoV-2 Test. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria for testing. Hospitals and reference laboratories can run the test on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems, which are widely available in the U.S. and around the world.
The CE-IVD test is also available in markets accepting the CE mark for patients with signs and symptoms of COVID-19 disease and living in affected areas where the SARS-CoV-2 virus is known to be present.
"Providing quality, high-volume testing capabilities will allow us to respond effectively to what the World Health Organization has characterized as a pandemic. It is important to quickly and reliably detect whether a patient is infected with SARS-CoV-2,” said Thomas Schinecker, CEO of Roche Diagnostics. “Over the last weeks, our emergency response teams have been working hard to bring this test to the patients. CE-mark certification and the FDA’s granting of EUA supports our commitment to give more patients access to reliable diagnostics which are crucial to combat this serious disease.”
The widely available Roche’s cobas 6800/8800 Systems, which are used to perform the cobas SARS-CoV-2 Test, provide test results in three and half hours and offer improved operating efficiency, flexibility, and fastest time-to-results with the highest throughput providing up to 96 results in about three hours and a total of 1,440 results for the cobas 6800 System and 4,128 results for the cobas 8800 System in 24 hours. The test can be run simultaneously with other assays provided by Roche for use on the cobas 6800/8800 Systems.
Upon authorization, Roche will have millions of tests a month available for use on the cobas 6800 and 8800 systems. Roche is committed to delivering as many tests as possible and is going to the limits of our production capacity.
Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related Products
Request Quote for All Products
LightCycler® 1536 Real-Time PCR System
LightCycler® 1536 Real-Time PCR System from Roche Applied Science - High Throughput - Redefined Forge ahead into a new era in high-throughput real-time PCR with the new LightCycler® 1536 RT-PCR Instrument. Precisely engineered for miniaturization and parallelization, this latest innovation reinforces Roche Applied Science as a global expert in real-time PCR. Take advantage of over ten years of publication-proven expertise with the next generation of groundbreaking LightCycler® Instrument technology, and break free from the limitations of the past. Advantages of the LightCycler 1536 Real-Time PCR System: Increase single-run throughput fourfold Generate 1536 data points in less than 50 minutes, with consistent sensitivity and accuracy Cut your cost per data point in half Benefit from next-generation miniturization that allows lower volumes of reagents and sample Acquire raw data you can trust Maintain continuity and comparability with your legacy results, even at extremely low reaction volumes The LightCycler® 1536 RT-PCR System builds on the high-performance optical and block cycler technologies of the proven LightCycler® 480 System. New features of the LightCycler® 1536 System include a unique 1536-well plate design, streamlined software, and the next generation of premium reagents.